title: Toward an effective strategy in glioblastoma treatment. Part II: RNA interference as a promising way to sensitize glioblastomas to temozolomide.
abstract: RNA interference (RNAi) is a strategy of gene regulation that has opened up many opportunities for the treatment of cancers, especially glioblastoma multiforme (GBM). This strategy reduced the expression of many proteins involved in the resistance of these tumors to anticancer drugs, particularly to temozolomide (TMZ). A significant research effort has gone into RNAi delivery and target selection for clinical application of this new discovery in the treatment of GBMs. However, some limitations must be resolved to enhance the safety of RNAi-based therapeutics and to reduce their immune response. In this review, the mechanism of RNAi will be described. Moreover, the opportunities offered by RNAi strategy to reverse the phenotype of these tumor cells as well as prospects and challenges ahead in the RNAi-based therapy will be discussed.
authors.affiliation: LUNAM Université, Angers, France; Inserm U1066, Micro et Nanomédicines Biomimétiques, IBS, Angers Cedex 9, France.
authors.forename: Khaled
authors.initials: K
authors.lastname: Messaoudi
authors.affiliation: LUNAM Université, Angers, France; Inserm U1066, Micro et Nanomédicines Biomimétiques, IBS, Angers Cedex 9, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Clavreul
authors.affiliation: LUNAM Université, Angers, France; Inserm U1066, Micro et Nanomédicines Biomimétiques, IBS, Angers Cedex 9, France; Service Pharmacie, CHU Angers, France. Electronic address: frederic.lagarce@univ-angers.fr.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Lagarce
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D001932:Brain Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D018014:Gene Transfer Techniques; D006801:Humans; D000067492:RNAi Therapeutics; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D014408:Biomarkers, Tumor; D003606:Dacarbazine; D000077204:Temozolomide